Long‐term weight control study I (weeks 0 to 34): The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

Michael Weintraub, Pavur R. Sundaresan, Manish Madan, Barbara Schuster, Andrew Balder, Louis Lasagna, Christopher Cox

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

To investigate the value of anorexiant medications as an adjunct to other forms of weight control therapy, we studied 121 people in a 34‐week, double‐blind clinical trial of 60 mg extended‐release fenfluramine plus 15 mg phentermine resin versus placebo added to behavior modification, caloric restriction, and exercise. Participants weighed 130% to 180% (154% ± 1.2%, mean ± SEM) of ideal body weight (1983 Metropolitan Life tables) and were in good health. By week 34, participants receiving active medication lost an average of 14.2 ± 0.9 kg, or 15.9% ± 0.9% of initial weight (n = 58), versus a loss of 4.6 ± 0.8 kg or 4.9% ± 0.9% of initial weight by subjects taking placebo (n = 54; p < 0.001). On visual analog scales, participants rated fenfluramine plus phentermine as more helpful than placebo (50.3 ± 0.5 versus 20.3 ± 0.3) and not bothersome (fenfluramine plus phentermine, 17.4 ± 0.3 versus 13.5 ± 0.2). Blood pressure decreased and pulse remained unchanged in both groups. Dry mouth was the most common adverse effect in subjects receiving fenfluramine plus phentermine; all adverse effects decreased after 4 weeks. Only nine participants left the study in the first 34 weeks. Two subjects from each group left the study as a result of adverse effects. Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise aided weight loss and continued to be efficacious for 34 weeks. Clinical Pharmacology and Therapeutics (1992) 51, 586–594; doi:

Original languageEnglish (US)
Pages (from-to)586-594
Number of pages9
JournalClinical Pharmacology & Therapeutics
Volume51
Issue number5
DOIs
StatePublished - Jan 1 1992

Fingerprint

Phentermine
Fenfluramine
Caloric Restriction
Behavior Therapy
Placebos
Weights and Measures
Ideal Body Weight
Life Tables
Clinical Pharmacology
Visual Analog Scale
Pulse
Mouth
Weight Loss
Clinical Trials
Blood Pressure
Health
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Long‐term weight control study I (weeks 0 to 34) : The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. / Weintraub, Michael; Sundaresan, Pavur R.; Madan, Manish; Schuster, Barbara; Balder, Andrew; Lasagna, Louis; Cox, Christopher.

In: Clinical Pharmacology & Therapeutics, Vol. 51, No. 5, 01.01.1992, p. 586-594.

Research output: Contribution to journalArticle

Weintraub, Michael ; Sundaresan, Pavur R. ; Madan, Manish ; Schuster, Barbara ; Balder, Andrew ; Lasagna, Louis ; Cox, Christopher. / Long‐term weight control study I (weeks 0 to 34) : The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. In: Clinical Pharmacology & Therapeutics. 1992 ; Vol. 51, No. 5. pp. 586-594.
@article{fa5be0b5edd54cefa71b5104466253e0,
title = "Long‐term weight control study I (weeks 0 to 34): The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo",
abstract = "To investigate the value of anorexiant medications as an adjunct to other forms of weight control therapy, we studied 121 people in a 34‐week, double‐blind clinical trial of 60 mg extended‐release fenfluramine plus 15 mg phentermine resin versus placebo added to behavior modification, caloric restriction, and exercise. Participants weighed 130{\%} to 180{\%} (154{\%} ± 1.2{\%}, mean ± SEM) of ideal body weight (1983 Metropolitan Life tables) and were in good health. By week 34, participants receiving active medication lost an average of 14.2 ± 0.9 kg, or 15.9{\%} ± 0.9{\%} of initial weight (n = 58), versus a loss of 4.6 ± 0.8 kg or 4.9{\%} ± 0.9{\%} of initial weight by subjects taking placebo (n = 54; p < 0.001). On visual analog scales, participants rated fenfluramine plus phentermine as more helpful than placebo (50.3 ± 0.5 versus 20.3 ± 0.3) and not bothersome (fenfluramine plus phentermine, 17.4 ± 0.3 versus 13.5 ± 0.2). Blood pressure decreased and pulse remained unchanged in both groups. Dry mouth was the most common adverse effect in subjects receiving fenfluramine plus phentermine; all adverse effects decreased after 4 weeks. Only nine participants left the study in the first 34 weeks. Two subjects from each group left the study as a result of adverse effects. Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise aided weight loss and continued to be efficacious for 34 weeks. Clinical Pharmacology and Therapeutics (1992) 51, 586–594; doi:",
author = "Michael Weintraub and Sundaresan, {Pavur R.} and Manish Madan and Barbara Schuster and Andrew Balder and Louis Lasagna and Christopher Cox",
year = "1992",
month = "1",
day = "1",
doi = "10.1038/clpt.1992.69",
language = "English (US)",
volume = "51",
pages = "586--594",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Long‐term weight control study I (weeks 0 to 34)

T2 - The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

AU - Weintraub, Michael

AU - Sundaresan, Pavur R.

AU - Madan, Manish

AU - Schuster, Barbara

AU - Balder, Andrew

AU - Lasagna, Louis

AU - Cox, Christopher

PY - 1992/1/1

Y1 - 1992/1/1

N2 - To investigate the value of anorexiant medications as an adjunct to other forms of weight control therapy, we studied 121 people in a 34‐week, double‐blind clinical trial of 60 mg extended‐release fenfluramine plus 15 mg phentermine resin versus placebo added to behavior modification, caloric restriction, and exercise. Participants weighed 130% to 180% (154% ± 1.2%, mean ± SEM) of ideal body weight (1983 Metropolitan Life tables) and were in good health. By week 34, participants receiving active medication lost an average of 14.2 ± 0.9 kg, or 15.9% ± 0.9% of initial weight (n = 58), versus a loss of 4.6 ± 0.8 kg or 4.9% ± 0.9% of initial weight by subjects taking placebo (n = 54; p < 0.001). On visual analog scales, participants rated fenfluramine plus phentermine as more helpful than placebo (50.3 ± 0.5 versus 20.3 ± 0.3) and not bothersome (fenfluramine plus phentermine, 17.4 ± 0.3 versus 13.5 ± 0.2). Blood pressure decreased and pulse remained unchanged in both groups. Dry mouth was the most common adverse effect in subjects receiving fenfluramine plus phentermine; all adverse effects decreased after 4 weeks. Only nine participants left the study in the first 34 weeks. Two subjects from each group left the study as a result of adverse effects. Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise aided weight loss and continued to be efficacious for 34 weeks. Clinical Pharmacology and Therapeutics (1992) 51, 586–594; doi:

AB - To investigate the value of anorexiant medications as an adjunct to other forms of weight control therapy, we studied 121 people in a 34‐week, double‐blind clinical trial of 60 mg extended‐release fenfluramine plus 15 mg phentermine resin versus placebo added to behavior modification, caloric restriction, and exercise. Participants weighed 130% to 180% (154% ± 1.2%, mean ± SEM) of ideal body weight (1983 Metropolitan Life tables) and were in good health. By week 34, participants receiving active medication lost an average of 14.2 ± 0.9 kg, or 15.9% ± 0.9% of initial weight (n = 58), versus a loss of 4.6 ± 0.8 kg or 4.9% ± 0.9% of initial weight by subjects taking placebo (n = 54; p < 0.001). On visual analog scales, participants rated fenfluramine plus phentermine as more helpful than placebo (50.3 ± 0.5 versus 20.3 ± 0.3) and not bothersome (fenfluramine plus phentermine, 17.4 ± 0.3 versus 13.5 ± 0.2). Blood pressure decreased and pulse remained unchanged in both groups. Dry mouth was the most common adverse effect in subjects receiving fenfluramine plus phentermine; all adverse effects decreased after 4 weeks. Only nine participants left the study in the first 34 weeks. Two subjects from each group left the study as a result of adverse effects. Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise aided weight loss and continued to be efficacious for 34 weeks. Clinical Pharmacology and Therapeutics (1992) 51, 586–594; doi:

UR - http://www.scopus.com/inward/record.url?scp=0026518794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026518794&partnerID=8YFLogxK

U2 - 10.1038/clpt.1992.69

DO - 10.1038/clpt.1992.69

M3 - Article

C2 - 1587072

AN - SCOPUS:0026518794

VL - 51

SP - 586

EP - 594

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -